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Purpose of the study
Life expectancy (LE) is an important health indicator
that informs decisions both by individuals and public
policymakers. The pattern of the HIV epidemic and LE
varies by country. Previous estimates of LE in HIV-
infected populations have included few UK patients[1].
We assess time trends, sex-differences and the impact of
delayed treatment on LE in treated HIV patients in the
UK and compare with the LE of the UK population.
Methods
We analysed data from the UK CHIC cohort study on
patients aged over 20 years who started cART in 1996-
2008 with CD4≤ 350cells/mm
2 (excluding injection drug
users). All-cause mortality was ascertained from clinic
records and by linkage to the death registry. Abridged life
tables were constructed from age-specific mortality rates
(5year age bands) to estimate LE for ages 20-65 years.
Results are presented as LE at exact age 20, the average
additional years that will be lived by a person after age 20,
according to the cross-sectional age-specific mortality
rates during the study period. We estimated LE overall
and by period (1996-99, 2000-02, 2003-05, 2006-08). We
compared LE in those treated for HIV with the UK popu-
lation stratified by sex. To assess the impact of late treat-
ment, we estimated LE stratified by CD4 cell count at start
of cART in those treated post 2000 who were ART-naive.
Results
1248/17661 eligible patients died during 91203 pyrs fup.
75% of patients were male, 58% white. Transmission risk
group was 54% MSM, 37% heterosexual and 9%
unknown. At start of cART, median age (IQR) was 37
(32-43) years, median CD4 cell count 166 (75-241) and
the proportion with no ART exposure prior to cART
increased from 54% in 1996-99 to 96% in 2006-08. LE
(standard errors) at exact age 20 years increased from
30.0 (1.2) to 45.8 (1.7) years from 1996-99 to 2006-08.
Over the study period LE for male patients was 39.5
(0.45) and for female 50.2(0.45) years compared with 57.8
and 61.6 years for men and women in the UK population
(1996-2006). LE was 37.9 (1.3), 41.0 (2.2) and 53.4 (1.2)
years in those starting cART with CD4<100, 100-199 and
200-350 cells/mm
2 respectively (N=9657).
Conclusions
LE of those treated for HIV-infection in the UK has
increased by over 15 years during 1996-2008, but
remains about 13 years less than that of the UK popula-
tion. The higher LE of women compared with men is
magnified in the HIV-infected population. Earlier diag-
nosis through improved screening and timely treatment
might increase LE.
Author details
1Bristol University, Social and Community Medicine, Bristol, UK.
2North Bristol
NHS Trust, Bristol, UK.
3UCL, Medical School, London, UK.
Published: 8 November 2010
Reference
1. The Antiretroviral Therapy Cohort Collaboration: Life expectancy of
individuals on combination antiretroviral therapy in high-income
countries: a collaborative analysis of 14 cohort studies. Lancet 2008,
372:293-99.
doi:10.1186/1758-2652-13-S4-O27
Cite this article as: May et al.: O233. Impact on life expectancy of late
diagnosis and treatment of HIV-1 infected individuals: UK CHIC. Journal
of the International AIDS Society 2010 13(Suppl 4):O27.
1Bristol University, Social and Community Medicine, Bristol, UK
Full list of author information is available at the end of the article
May et al. Journal of the International AIDS Society 2010, 13(Suppl 4):O27
http://www.jiasociety.org/content/13/S4/O27
© 2010 May et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.